PQE Group, a leading consultancy in the Life Science sector, has launched its new Regulated Artificial Intelligence & Data Analytics division, marking a significant advancement since the introduction of AI-based tools in industrial settings. With over 2000 employees, the Italian Group is positioning itself at the forefront of technological innovation in Life Sciences. The division aims to optimize business processes, ensure regulatory compliance, and accelerate innovation through AI-driven decision optimization and risk reduction services, all aligned with industry standards.
Danilo Neri, Partner & Vice President Executive of PQE Group, highlighted the evolving regulatory landscape: “Regulators are increasingly setting expectations for AI solutions, necessitating detailed documentation to ensure transparency and performance of each tool. The recent approval of the AI Act in the European Union represents a major regulatory milestone, emphasizing the importance of explainability and accountability. It’s crucial that penalties are effectively enforced to safeguard consumer, worker, and citizen interests while fostering innovation and market competitiveness.”
PQE Group’s validation approach meets current regulatory standards for machine learning-based tools and Generative AI solutions, ensuring robust compliance and tailored solutions for clients.
In collaboration with GenAIz, a Canadian company specializing in AI-driven decision support, PQE Group enhances its service capabilities. GenAIz’s platform accelerates decision-making and business insights, complementing PQE Group’s global footprint spanning over 45 offices worldwide. Led by Catherine Lunardi, CEO of GenAIz and a key advocate on AI and wellbeing at the G7, this partnership reinforces PQE Group’s commitment to delivering innovative solutions aligned with GxP regulations and upcoming industry-wide rules, such as the European AI Act.
The Regulated Artificial Intelligence & Data Analytics division will be unveiled at a panel discussion and networking event in Rockville, MD, on July 17, 2024. Experts will explore AI regulations and future trends in life sciences, underscoring PQE Group’s dedication to advancing the pharmaceutical and medical device industries.
